Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest news

AACR meeting 2016: Nerviano Medical Sciences presents data on two novel, potent and highly selective anti-tumor agents.

Nerviano, Italy, April 14th – Nerviano Medical Sciences will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16-20, New Orleans, Louisiana, USA.
New data will be presented regarding a novel potent and highly selective PARP-1 inhibitor, that potentially represents a significant advancement over currently available agents, which target both PARP-1 and -2. NMS-P293 is selectively active on tumor cell lines defective in the HR DNA repair pathway, such as BRCA and pTEN mutated lines, while sparing DNA repair proficient cells and normal myelocytes. Its highly favorable preclinical characteristics make this compound a promising candidate for further development.

The second presentation regards novel, potent and selective ATP-competitive MELK kinase inhibitors identified by means of high-throughput screening of the Nerviano Medical Sciences proprietary compound collection. MELK gene expression levels correlate inversely with poor prognosis in breast cancer, prostate cancer and glioblastoma patients, with recent findings also underlining the oncogenic role of this kinase in triple negative breast cancer (TNBC), a category of high-grade and invasive tumors.
Presentation title: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability
Authors: Alessia Montagnoli et al
Meeting: AACR Annual Meeting 2016, Abstract number 1223
Presentation Time: Monday, Apr 18, 2016, 8:00 AM -12:00 PM

Presentation title: 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines
Authors: Patrizia Carpinelli et al
Meeting: AACR Annual Meeting 2016, Abstract number 3795
Presentation Time: Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM

The full abstracts can be found on the conference website:
Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
Oxford, UK; San Jose, CA and Nerviano, Italy – 04th April 2016 – Oxford BioTherapeutics (OBT), a company developing a range of innovative Antibody Drug Conjugates (ADCs) for the treatment of cancer and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer today announce that they have signed a license agreement that will allow OBT to utilise Nerviano’s novel ‘payload’ (drug-linker) technology to expand its ADC development portfolio, which is designed to meet multiple unmet needs in the field of cancer.
Under the agreement, OBT has licensed Nerviano’s payload technology for an exclusive OBT target for development of an ADC. The agreement also allows for evaluation of additional ADC development candidates with favourable activity/safety profiles, for which OBT will have the opportunity to exercise options to further licenses to the drug-linker technology on an antigen-exclusive basis. As a result of this agreement, Nerviano will receive undisclosed fees, development linked milestones and royalties for granting OBT access to its technology. Nerviano will lead the effort in the manufacture and supply of its novel drug-linker technology.
OBT’s current ADC pipeline has been generated using the Company’s proprietary OGAP® targeting platform, and includes novel antibodies and proven drug-linker technologies accessed from leading companies in the field. The deal with Nerviano gives OBT access to a new payload technology based on a next-generation duocarmycin analogue.
Nerviano’s novel drug-linker technology of new DNA intercalating agents is based on a proprietary thienoindole scaffold, characterized both by potent antitumor activity and by physicochemical properties that are highly compatible with deployment as antibody payloads. Nerviano’s core technologies in the field further include: medicinal chemistry expertise, know-how for establishing proof of concept, GMP manufacturing of payloads as well as efficacy and safety profiling of ADC’s.
Christian Rohlff, CEO of OBT, commented: “We are making excellent progress towards our goal of becoming a world leader in developing ADCs for the treatment of cancer. We are very pleased to have signed today’s deal with Nerviano as it provides us with access to its next generation drug linker technology for ADCs. We are looking forward to working with the Nerviano team to develop additional ADC candidates that are designed to address unmet needs in cancer.”

Andrea Agazzi, President of NMS Group, commented: “We are pleased to have signed this licensing deal with OBT. We believe that their expertise in ADCs will allow us together to fully capitalise on the significant potential of Nerviano’s next generation drug linker technologies to develop the ADCs that are clearly needed to improve the lives of patients with cancer.”

About Oxford BioTherapeutics:
Oxford BioTherapeutics is a privately-held biotechnology company which is developing a range of innovative antibody-based therapeutics with antibody drug conjugate (ADCs) and immuno-oncology approaches for the treatment of cancer. The company’s therapies are directed at targets selected from an exclusive cancer proteome database generated on its proprietary OGAP® platform targeting cell surface proteins. These incorporate novel antibody and drug-linker technologies accessed from leading companies in the field. OGAP® is the world’s largest cancer library with over 5,000 cancer cell proteins providing unique, highly-valuable oncology targets.

Oxford BioTherapeutics entered a strategic agreement with Menarini in 2012 to accelerate the development of its ADCs, under which Menarini provides clinical and manufacturing expertise and potential investment of up to $1 billion, plus potential milestone and royalty payments, in exchange for commercial rights in Europe, Asia and Latin America. Oxford BioTherapeutics retains commercial rights in the US and Japan.

Oxford BioTherapeutics has a strong management team with significant experience in developing antibody-based therapies. The company is based in Oxford, UK and San Jose, CA.

For further information, please see, 


Accelera appointed as a member of EU-NETVAL.
Nerviano, Italy – 01st February 2016 – Accelera is pleased to inform that its test facility has been selected for inclusion within the European Union Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL), established by the EU Commission in context of Directive 2010/63 for the protection of animals used for scientific purposes.
EU-NETVAL's mission is to provide support for EURL ECVAM validation studies that serve to assess the reliability and relevance of alternative methods that have a potential to replace, reduce or refine (3Rs) the use of animals for scientific purposes.
The selection was based on specific technical skills, competence, and compliance to the existing guidance on Good Laboratory Practices (GLP).
The appointment of Accelera Srl within EU-NETVAL recognizes both the scientific excellence of its Team, and its proactivity in the identification and development of new alternative methods aimed at the translation into regulatory testing of the 3Rs concept, and finally contributing to overall animal welfare principles.
General information on EU-NETVAL is available on their website at


Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial
Surenes (France), and, Nerviano, 24th September, 2015 – Servier and Nerviano Medical Sciences together announced today the start of a first in Human clinical trial of the drug S 81694 (NMS-P153), an inhibitor of the mitotic checkpoint kinase MPS1 discovered by Nerviano Medical Sciences and thereafter acquired and further developed by Servier.

The study is an open-label, non-randomized, multicenter international trial in patients with advanced or metastatic solid tumors who have failed previous therapies. An initial dose-escalation stage will be followed by expansion in specific solid tumors. The study is designed to confirm the safety and pharmacokinetics of S 81694, administered as a single agent. Secondary objectives include initial assessment of efficacy and determination of the recommended dose for phase 2.
Servier is the sponsor of the study, which is being conducted in Belgium and The Netherlands by Nerviano’s clinical affiliate Clioss. S 81694 is supplied by Nerpharma, the CMO affiliate of Nerviano.
Jean-Pierre Abastado, Ph.D., Director of the Oncology Innovation Therapeutic Pole at Servier, said: “We are very enthusiastic about the initiation of this study as S 81694 (NMS-P153) is a novel potent inhibitor of MPS1. MPS1 represents an original target overexpressed during the M phase in many types of cancers. S 81694 is highly selective for MPS1 and a brief exposure to S 81694 is sufficient to commit cancer cells to death”.

Emmanuel Canet, M.D., PhD, President of Servier R&D stressed that “With the entry in clinical phase of this new antitumoral compound, Servier is reinforcing its commitment to provide innovative therapeutic solutions for unmet needs in patients with serious illnesses”.

Arturo Galvani, Ph.D., Director of Drug Discovery at Nerviano Medical Sciences commented: “we have been working together with Servier, a company engaged in cutting-edge research in oncology, in an outstanding collaboration to successfully advance S81694 to clinical development and hope that this first step will further translate into clinical benefit for patients with cancer”.

About MPS1:
MPS1 (also known as TTK) is a conserved kinase which is highly expressed in a number of human tumors of different origin. MPS1 plays a critical role in the control of a stage of the cell division cycle known as mitosis. During mitosis, MPS1 is involved in regulation of the spindle assembly checkpoint, a mechanism required for chromosome alignment and segregation. The activity of this checkpoint has been shown to be up-regulated in aneuploid tumors, comprising approximately 90% of solid and 70% of hematological cancers. In accelerating mitosis, MPS1 inhibitors have a novel mode of action as compared to currently available drugs targeting this stage of cell division.









Vinaora Nivo Slider
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.